DK3378859T3 - Benzofuranderivater, fremgangsmåde til fremstilling deraf og anvendelse deraf i medicin - Google Patents

Benzofuranderivater, fremgangsmåde til fremstilling deraf og anvendelse deraf i medicin Download PDF

Info

Publication number
DK3378859T3
DK3378859T3 DK16865671.8T DK16865671T DK3378859T3 DK 3378859 T3 DK3378859 T3 DK 3378859T3 DK 16865671 T DK16865671 T DK 16865671T DK 3378859 T3 DK3378859 T3 DK 3378859T3
Authority
DK
Denmark
Prior art keywords
benzofurand
medicine
derivatives
preparing
benzofurand derivatives
Prior art date
Application number
DK16865671.8T
Other languages
English (en)
Inventor
Biao Lu
Xiaodong Shen
Mingxun He
Dong Liu
Minsheng Zhang
Original Assignee
Jiangsu Hengrui Medicine Co
Shanghai hengrui pharmaceutical co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co, Shanghai hengrui pharmaceutical co ltd filed Critical Jiangsu Hengrui Medicine Co
Application granted granted Critical
Publication of DK3378859T3 publication Critical patent/DK3378859T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)
DK16865671.8T 2015-11-19 2016-11-02 Benzofuranderivater, fremgangsmåde til fremstilling deraf og anvendelse deraf i medicin DK3378859T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201510800975 2015-11-19
PCT/CN2016/104318 WO2017084494A1 (zh) 2015-11-19 2016-11-02 苯并呋喃类衍生物、其制备方法及其在医药上的应用

Publications (1)

Publication Number Publication Date
DK3378859T3 true DK3378859T3 (da) 2020-01-20

Family

ID=58717310

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16865671.8T DK3378859T3 (da) 2015-11-19 2016-11-02 Benzofuranderivater, fremgangsmåde til fremstilling deraf og anvendelse deraf i medicin

Country Status (22)

Country Link
US (2) US10759787B2 (da)
EP (1) EP3378859B1 (da)
JP (1) JP6828229B2 (da)
KR (1) KR20180081587A (da)
CN (1) CN107428742B (da)
AU (1) AU2016357900B2 (da)
BR (1) BR112018007876B1 (da)
CA (1) CA3002436A1 (da)
DK (1) DK3378859T3 (da)
ES (1) ES2760510T3 (da)
HK (1) HK1243414A1 (da)
HR (1) HRP20192209T1 (da)
HU (1) HUE047785T2 (da)
LT (1) LT3378859T (da)
MX (1) MX2018005019A (da)
PL (1) PL3378859T3 (da)
PT (1) PT3378859T (da)
RS (1) RS59763B1 (da)
RU (1) RU2727198C2 (da)
SI (1) SI3378859T1 (da)
TW (1) TWI718207B (da)
WO (1) WO2017084494A1 (da)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10266542B2 (en) 2017-03-15 2019-04-23 Mirati Therapeutics, Inc. EZH2 inhibitors
US11155537B2 (en) 2017-05-18 2021-10-26 Jiangsu Hengrui Medicine Co., Ltd. Crystal of benzofuran derivative free base and preparation method
MY201580A (en) * 2017-05-18 2024-03-02 Jiangsu Hengrui Medicine Co Use of ezh2 inhibitor combined with btk inhibitor in preparing drug for treating tumor
TWI717656B (zh) * 2017-11-10 2021-02-01 大陸商江蘇恒瑞醫藥股份有限公司 苯並呋喃衍生物的製備方法
DK4043466T3 (da) 2018-01-31 2024-09-30 Mirati Therapeutics Inc PRC2-inhibitorer
CN110179796B (zh) * 2018-02-23 2023-01-24 江苏恒瑞医药股份有限公司 一种苯并呋喃类衍生物的组合物及制备方法
EP3781561B1 (en) * 2018-04-18 2024-03-13 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
CN110563722A (zh) * 2018-06-06 2019-12-13 上海青煜医药科技有限公司 吡啶或哒嗪并环化合物及其应用
TW202027787A (zh) * 2018-09-29 2020-08-01 大陸商江蘇恆瑞醫藥股份有限公司 Ezh2抑制劑與免疫檢查點抑制劑聯合在製備治療腫瘤的藥物中的用途
WO2020192650A1 (zh) 2019-03-25 2020-10-01 上海华汇拓医药科技有限公司 酰胺类化合物制备方法及其在医药领域的应用
CN113302185B (zh) * 2019-04-29 2024-04-09 上海和誉生物医药科技有限公司 苯并呋喃-6-甲酰胺衍生物、其制备方法和药学上的应用
WO2020228591A1 (zh) * 2019-05-10 2020-11-19 江苏恒瑞医药股份有限公司 一种6-取代氨基苯并呋喃化合物的制备方法
CN110003187B (zh) * 2019-05-10 2021-11-05 南京工业大学 一种多氟烷基取代苯并呋喃类化合物及其制备方法
CN112007162B (zh) * 2019-05-30 2023-05-12 江苏恒瑞医药股份有限公司 Ezh2抑制剂与免疫检查点抑制剂、vegfr抑制剂联合在制备治疗肿瘤药物中的用途
CN110172448B (zh) * 2019-05-30 2020-07-28 中南大学湘雅二医院 一种滑膜肉瘤细胞系hSS-005R及其子代细胞系
WO2020259667A1 (zh) * 2019-06-28 2020-12-30 江苏恒瑞医药股份有限公司 Tlr激动剂与抗ox40抗体或其抗原结合片段联合在制备治疗肿瘤的药物中的用途
US20220257577A1 (en) 2019-07-24 2022-08-18 Constellation Pharmaceuticals, Inc. Ezh2 inhibition in combination therapies for the treatment of cancers
WO2021063332A1 (zh) * 2019-09-30 2021-04-08 江苏恒瑞医药股份有限公司 一种ezh2抑制剂与cdk4/6抑制剂联合在制备治疗肿瘤药物中的用途
WO2021063340A1 (zh) * 2019-09-30 2021-04-08 江苏恒瑞医药股份有限公司 Ezh2抑制剂与免疫检查点抑制剂、酪氨酸激酶抑制剂联合在制备治疗肿瘤药物中的用途
WO2021063331A1 (zh) * 2019-09-30 2021-04-08 江苏恒瑞医药股份有限公司 EZH2抑制剂与含有TGF-β受体的融合蛋白联合在制备治疗肿瘤的药物中的用途
CN112870365A (zh) * 2019-11-29 2021-06-01 江苏恒瑞医药股份有限公司 Ezh2抑制剂和/或parp抑制剂与化疗药物联合在制备治疗肿瘤药物中的用途
MX2024002538A (es) 2021-08-30 2024-03-19 Jiangsu Hengrui Pharmaceuticals Co Ltd Uso de un inhibidor de la ezh2 en la preparacion de farmacos para el tratamiento del linfoma de linfocitos t.
AU2022365986A1 (en) 2021-10-15 2024-05-09 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Method for preparing benzofuran derivative
TW202415655A (zh) 2022-06-13 2024-04-16 美商樹線生物科學公司 1,8—萘啶—2—酮異雙功能bcl6降解劑
WO2023244918A1 (en) 2022-06-13 2023-12-21 Treeline Biosciences, Inc. Quinolone bcl6 bifunctional degraders

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110275630A1 (en) 2003-06-02 2011-11-10 Abbott Laboratories Isoindolinone kinase inhibitors
AU2009214194B2 (en) * 2008-02-14 2012-05-17 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
WO2012005805A1 (en) * 2010-05-07 2012-01-12 Glaxosmithkline Llc Azaindazoles
ES2534804T3 (es) 2010-05-07 2015-04-28 Glaxosmithkline Llc Indazoles
PT2566327T (pt) * 2010-05-07 2017-05-26 Glaxosmithkline Llc Indoles
EP2410171A1 (en) 2010-07-23 2012-01-25 Ewt Ip B.V. Wind turbine having a rotor with hub
SG180031A1 (en) 2010-10-15 2012-05-30 Agency Science Tech & Res Combination treatment of cancer
WO2012118812A2 (en) * 2011-02-28 2012-09-07 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
TW201733984A (zh) * 2011-04-13 2017-10-01 雅酶股份有限公司 經取代之苯化合物
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
WO2013039988A1 (en) * 2011-09-13 2013-03-21 Glax0Smithkline Llc Azaindazoles
KR20140082742A (ko) * 2011-09-30 2014-07-02 글락소스미스클라인 엘엘씨 암을 치료하는 방법
WO2013067300A1 (en) 2011-11-04 2013-05-10 Glaxosmithkline Intellectual Property (No. 2) Limited Method of treatment
WO2013173441A2 (en) 2012-05-16 2013-11-21 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors
UA111305C2 (uk) 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
EP2991980B1 (en) 2013-04-30 2019-01-02 Glaxosmithkline Intellectual Property (No. 2) Limited Enhancer of zeste homolog 2 inhibitors
WO2015077194A1 (en) * 2013-11-22 2015-05-28 Bristol-Myers Squibb Company Inhibitors of lysine methyl transferase
RU2679131C2 (ru) * 2014-03-17 2019-02-06 Дайити Санкио Компани, Лимитед Производное 1,3-бензодиоксола

Also Published As

Publication number Publication date
AU2016357900B2 (en) 2020-09-17
SI3378859T1 (sl) 2020-03-31
EP3378859B1 (en) 2019-10-30
HUE047785T2 (hu) 2020-05-28
PL3378859T3 (pl) 2020-04-30
HRP20192209T1 (hr) 2020-07-24
US11059811B2 (en) 2021-07-13
CN107428742B (zh) 2020-05-08
US20200354349A1 (en) 2020-11-12
CN107428742A (zh) 2017-12-01
RS59763B1 (sr) 2020-02-28
RU2018119173A (ru) 2019-12-19
WO2017084494A1 (zh) 2017-05-26
EP3378859A1 (en) 2018-09-26
MX2018005019A (es) 2018-06-13
US20180327394A1 (en) 2018-11-15
TWI718207B (zh) 2021-02-11
CA3002436A1 (en) 2017-05-26
JP2018538257A (ja) 2018-12-27
BR112018007876B1 (pt) 2023-10-17
EP3378859A4 (en) 2018-09-26
LT3378859T (lt) 2020-01-27
JP6828229B2 (ja) 2021-02-10
AU2016357900A1 (en) 2018-05-24
ES2760510T3 (es) 2020-05-14
TW201718561A (zh) 2017-06-01
HK1243414A1 (zh) 2018-07-13
RU2018119173A3 (da) 2020-02-13
RU2727198C2 (ru) 2020-07-21
US10759787B2 (en) 2020-09-01
KR20180081587A (ko) 2018-07-16
BR112018007876A2 (pt) 2018-10-30
PT3378859T (pt) 2019-12-11

Similar Documents

Publication Publication Date Title
DK3378859T3 (da) Benzofuranderivater, fremgangsmåde til fremstilling deraf og anvendelse deraf i medicin
DK3354649T3 (da) Oxaspiroderivat, fremstillingsmetode derfor og anvendelser deraf i lægemidler
DK3453707T3 (da) Benzazepinderivat, fremgangsmåde til fremstilling, farmaceutisk sammensætning og anvendelse deraf
DK3486242T3 (da) Oxopicolinamidderivat, fremgangsmåde til fremstilling deraf og farmaceutisk anvendelse deraf
DK3209308T3 (da) Aktiverede bifidobakterier og fremgangsmåder til anvendelse deraf
DK3505519T3 (da) Pyridinamin-substituerede heterotricyclo-forbindelser, fremstilling deraf og anvendelse i medicin
DK3643709T3 (da) Isoindolinderivat, mellemprodukt, fremgangsmåde til fremstilling, farmaceutisk sammensætning og anvendelse deraf
DK3153169T3 (da) Fremgangsmåde til behandling af tumor, farmaceutisk sammensætning og medicinæskesæt
DK3265043T3 (da) Hjælpemiddel til patienttransport og -træning
DK3909972T5 (da) Pd1-cd28-fusionsproteiner og disses anvendelse i medicin
DK3259597T3 (da) Pvrig-polypeptider og fremgangsmåder til behandling
DK3559000T3 (da) Benzimidazol-derivater, fremgangsmåder til fremstilling og anvendelser deraf
DK3394065T3 (da) Tetrahydropyranyl-amino-pyrrolopyrimidinon og fremgangsmåder til anvendelse deraf
DK3305310T3 (da) Onkolytisk virusformulering og fremgangsmåde til fremstilling deraf
DK3094640T3 (da) Fremgangsmåder til steril kromatografi og fremstilling
DK3380525T3 (da) Farmaceutiske formuleringer og fremgangsmåder til anvendelse deraf
DK3357343T3 (da) Fedtsammensætning og fremgangsmåde til fremstilling heraf
DK3185872T3 (da) Formulering af testosteron og metoder til behandling hermed
DK3183201T3 (da) Spilsamling og fremgangsmåde til anvendelse
DK3495482T3 (da) Fremgangsmåde til fremstilling af dna-enhedssammensætning og fremgangsmåde til frembringelse af concatenat-dna
DK3353191T3 (da) Cykliske polypeptider, fremgangsmåde til opnåelse deraf og terapeutisk anvendelse deraf
DK3404024T3 (da) Quinazolinonderivat, fremgangsmåde til fremstilling deraf, farmaceutisk sammensætning og anvendelser
DK3212166T3 (da) Varme-steriliseret formulering omfattende chitosan og fremgangsmåde til fremstilling deraf
DK3387019T3 (da) Relaxin-immunoglobulinfusionsproteiner og anvendelsesfremgangsmåder
DK3057589T3 (da) (s)-pirlindol og farmaceutisk acceptable salte heraf til anvendelse i medicin